News

Quebec implements public reimbursement of Pluvicto® - a defining milestone for radioligand therapy in Canada
MONTREAL, July 3, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto ® (lutetium ( 177 Lu) vipivotide tetraxetan injection) is ...